CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Sale | −5,022 | $86.67 | $435K | 23,513 |
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Sale | −134 | $86.65 | $12K | 23,379 |
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −206 | 7,516 | ||
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −1,544 | 18,456 | ||
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise · Incentive Stock Option (right to buy) | −145 | 0 | ||
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −5,022 | 16,179 | ||
| 2024-05-16 | Espinoza Octavio Chief Financial Officer | Sale | −2,264 | $86.00 | $195K | 21,618 |
| 2024-05-15 | Espinoza Octavio Chief Financial Officer | Sale | −5,873 | $86.01 | $505K | 23,882 |
| 2024-05-14 | Korenberg Matthew E President & Chief Operating | Sale | −13,638 | $85.08 | $1.2M | 86,783 |
| 2024-05-14 | Korenberg Matthew E President & Chief Operating | Sale | −520 | $85.68 | $45K | 86,263 |
| 2024-05-13 | Korenberg Matthew E President & Chief Operating | Sale | −3,440 | $84.54 | $291K | 100,421 |
| 2024-05-09 | Gray Nancy Ryan Director | Sale | −934 | $83.20 | $78K | 5,633 |
| 2024-05-09 | Reardon Andrew Chief Legal Officer & | Option exercise | +10,000 | $52.27 | $523K | 32,205 |
| 2024-05-09 | Reardon Andrew Chief Legal Officer & | Sale | −10,000 | $83.04 | $830K | 22,205 |
| 2024-05-09 | Reardon Andrew Chief Legal Officer & | Option exercise · Non-Qualified Stock Option (right to buy) | −10,000 | 62,944 | ||
| 2024-04-30 | Aryeh Jason Director | Option exercise | +2,406 | $52.30 | $126K | 76,828 |
| 2024-04-30 | Aryeh Jason Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,406 | 0 | ||
| 2024-04-24 | KOZARICH JOHN W Director | Option exercise | +2,893 | $39.35 | $114K | 42,523 |
| 2024-04-24 | KOZARICH JOHN W Director | Option exercise · Non-Qualified Stock Option (right to buy) | −2,893 | 0 | ||
| 2024-03-25 | Davis Todd C Chief Executive Officer | Option exercise | +7,448 | $46.20 | $344K | 111,593 |
Page 22 of 43 · 858 trades